You are here:Home1/casestudy2/ASP sold certain assets to Roivant Sciences GmbH
ASP sold certain assets to Roivant Sciences GmbH
Background: Avadel Specialty Pharmaceuticals, LLC (“ASP”), based in Chesterfield, MO, is a pharmaceutical company engaged in the business of commercializing, marketing, and distributing NOCTIVA™ (desmopressin acetate) nasal spray.
Cassel Salpeter:
Served as financial advisor to the Company
Ran a competitive sales process, identifying and contacting over 100 strategic and financial parties
Provided assistance throughout all phases of the Chapter 11 Section 363 sales process, due diligence, and auction.
Challenges:
NOCTIVA™ had limited sales and required a full commercialization effort to make the drug financially successful
ASP entered into an unfavorable license agreement which potential bidders ultimately had to renegotiate
Outcome: On April 15, 2019, the court approved the sale of certain ASP assets to Roivant Sciences GmbH, headquartered in Basel, Switzerland.
https://www.casselsalpeter.com/wp-content/uploads/2019/11/Avadel_logo.jpg250250roaradminhttp://www.casselsalpeter.com/wp-content/uploads/2021/05/CS-Logo-for-Assets-Post-10-Year-Branding_Website_04.28.21_Draft01.pngroaradmin2019-04-01 17:22:402020-12-08 14:37:00ASP sold certain assets to Roivant Sciences GmbH
